ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 111,83
0,24%
Dow Jones
39 386,39
-0,72%
DAX
18 685,41
0,02%
Brent Oil
81,975
0,55%
Bitcoin
67 959,23
-1,66%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Bolt Biotherapeutics Inc (BOLT)

  7. Bolt Biotherapeutics Inc (BOLT) Actualités

BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BOLT
DateHeureSourceTitreSymboleSociété
20/05/202419h22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BOLTBolt Biotherapeutics Inc
15/05/202423h43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
14/05/202422h05GlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamNASDAQ:BOLTBolt Biotherapeutics Inc
21/03/202421h05GlobeNewswire Inc.Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
06/03/202419h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
27/02/202413h00GlobeNewswire Inc.Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
13/02/202403h41Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BOLTBolt Biotherapeutics Inc
06/02/202419h09Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
21/12/202313h30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:BOLTBolt Biotherapeutics Inc
05/12/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®NASDAQ:BOLTBolt Biotherapeutics Inc
09/11/202322h05GlobeNewswire Inc.Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
07/11/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
23/10/202316h30GlobeNewswire Inc.Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressNASDAQ:BOLTBolt Biotherapeutics Inc
18/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
17/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersNASDAQ:BOLTBolt Biotherapeutics Inc
16/10/202313h00GlobeNewswire Inc.Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023NASDAQ:BOLTBolt Biotherapeutics Inc
28/09/202313h00GlobeNewswire Inc.Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersNASDAQ:BOLTBolt Biotherapeutics Inc
12/09/202314h05GlobeNewswire Inc.Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042NASDAQ:BOLTBolt Biotherapeutics Inc
05/09/202322h15GlobeNewswire Inc.Bolt Biotherapeutics to Participate in September Investor ConferencesNASDAQ:BOLTBolt Biotherapeutics Inc
07/08/202322h10GlobeNewswire Inc.Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
03/08/202313h30GlobeNewswire Inc.Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerNASDAQ:BOLTBolt Biotherapeutics Inc
31/07/202323h27GlobeNewswire Inc.Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:BOLTBolt Biotherapeutics Inc
14/06/202323h22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BOLTBolt Biotherapeutics Inc
13/06/202322h56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BOLTBolt Biotherapeutics Inc
30/05/202314h00PR Newswire (US)BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesNASDAQ:BOLTBolt Biotherapeutics Inc
25/05/202323h05GlobeNewswire Inc.Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
11/05/202322h05GlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
28/04/202322h18Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BOLTBolt Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BOLT

Dernières Valeurs Consultées

LSE
QH94
Morg.st.b.v 26
BIT
P1UWI6
NLBNPIT1UWI6 20991231 16...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés